Held by 2 specialist biotech funds
**Signal Note: Eventide initiates Southern Company position** This $9.7M position in Southern Company (SO) appears inconsistent with Eventide's biotech-focused mandate and values-based strategy, suggesting either portfolio diversification into utilities/clean energy or a data error. The position size (~0.1% of typical biotech holdings) and timing warrant clarification on whether this reflects ESG criteria alignment (renewable energy transition) or represents a portfolio rebalancing outside core competencies.